# A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma

> **NCT01562197** · PHASE2 · COMPLETED · sponsor: **Bart Neyns** · enrollment: 56 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** axitinib
- **DRUG:** Axitinib plus Lomustine

## Key facts

- **NCT ID:** NCT01562197
- **Lead sponsor:** Bart Neyns
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2018-08
- **Final completion:** 2018-12
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562197, "A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01562197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*